Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

Thanks Leo: Brilacidin Acquired On 9/4/2013

PolyMedix filed for Chapter 7 bankruptcy protection on April 1, 2013. Following a due diligence process, Cellceutix submitted a “stalking horse” bid for the PolyMedix assets in August. On Wednesday, September 4, the Bankruptcy Court for the District of Delaware approved the asset purchase agreement. In the transaction, Cellceutix assumes none of the debt associated with PolyMedix. The purchase price was $2.1 million in cash and 1.4 million shares of CTIX stock.

http://www.ipharminc.com/press-release/2016/11/16/cellceutix-acquires-polymedix-assets-from-bankruptcy-court-gains-ownership-of-two-clinical-stage-drugs-multiple-compounds-and-equipment-assets

IPIX would not be in this enviable pandemic-position had it not been for the alert and quick actions of Leo. And while Leo has had his missteps...missteps do not necessarily mean mismanagement. At this point in time for IPIX, it is more important to look ahead rather than back.

At last, Leo has the wind at his back. First a little history. Brilacidin is being investigated as a vaccine by George Mason University and as a broad-spectrum antiviral by a U.S. government, RBL.

WAKEFIELD, MA – March 17, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today further details on the Material Transfer Agreement (MTA) signed with a leading public health-focused U.S. university and top coronavirus expert. Under the terms of the confidential agreement, virologists plan to evaluate the potential antiviral properties of Brilacidin, the Company’s lead defensin-mimetic drug candidate, toward developing Brilacidin as a potential novel coronavirus (COVID-19) vaccine.

Vaccines containing defensins as adjuvants have been shown, both in vivo and in vitro, to activate the primary innate antiviral immune response and mediate other immunomodulatory activities against a number of viruses, including coronaviruses. Defensins and their mimetics, like Brilacidin, thus represent promising therapeutics developed as vaccines to target COVID-19, the deadly respiratory disease caused by the novel coronavirus SARS-CoV-2, which has emerged as a worldwide pandemic.

This new research is independent of that being conducted on Brilacidin at one of the U.S. 12 Regional Biocontainment Labs (RBL). The RBL is testing Brilacidin’s potential inhibitory activity as a small molecule drug against SARS-CoV-2, the novel coronavirus responsible for COVID-19.

http://www.ipharminc.com/press-release/2020/3/17/innovation-pharmaceuticals-brilacidin-to-be-researched-as-possible-novel-coronavirus-covid-19-vaccine-brilacidin-now-being-tested-as-drug-and-vaccine-at-different-institutions

So, Brilacidin is on the "radar" of the U.S. Gov't just as the Biden administration announces plans to spend $36B on the development of new vaccines and therapeutics.

The U.S. would spend a total of $24.2 billion to develop and test new vaccines for a range of viruses and make improvements to vaccine distribution and manufacturing.

The plan also calls for spending $11.8 billion on therapeutics, which would allow U.S. scientists and drugmakers develop new antivirals and other drugs and ensure large-scale manufacturing capacity for monoclonal antibody treatments.

https://www.cnbc.com/2021/09/03/covid-biden-administration-unveils-65-billion-plan-to-combat-next-pandemics.html

Even before this announcement, the global outlook for the antiviral drug-therapy (AVDT) was bright.

The [AVDT] market is then expected to grow at a CAGR of 8.3% from 2021 and reach $74,385.9 million [=$74.3B] in 2023. The market is expected to reach $ 87,230.5 million [=$87.2B] in 2025, and $ 130,125.3 million [=$130.1B] in 2030.

https://www.businesswire.com/news/home/20210210005504/en/Global-Anti-Viral-Drug-Therapy-Market-2020-to-2030---Opportunities-and-Strategies-with-COVID-19-Implications-and-Growth---ResearchAndMarkets.com

In the much shorter term and as we await B-COVID's data lock and subsequent top-line data, which the evidence indicates should be very good,it seems IPIX has the short term money (EUA) as well as the long term money in the AVDT market covered very well.

All of this is the wind at IPIX's back and without Leo we would not be in this position. Think about this as you review B-COVID's P-2 topline results.

So, once again, thank you Leo. We wouldn't be here without you.